Mineralocorticoid Receptor Antagonists Are Associated With Reduction in Atrial Fibrillation: A Meta-Analysis of Randomised Controlled Trials

Mineralocorticoid receptor antagonists (MRAs) have emerged as potential therapy to target the underlying arrhythmogenic substrate in atrial fibrillation (AF). However, inconsistent results of MRAs effect on AF have been reported. This study assessed the effect of MRAs on new-onset and recurrent AF.